Patents Assigned to GemVax AS
-
Publication number: 20170143806Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: ApplicationFiled: November 4, 2016Publication date: May 25, 2017Applicant: GemVax & KAEL Co., Ltd.Inventors: Sang Jae KIM, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Publication number: 20170128557Abstract: Provided is a dendritic cell therapeutic agent, and more particularly, a composition which include dendritic cells activated by peptides including a telomerase-derived peptide, the composition administered to treat an individual having disease and disorder symptoms which require target-specific treatments. Also, provided is a therapeutic method effective on diseases requiring target-specific immunotherapy. In the method, co-administration of the dendritic cell therapeutic agent and an immunotherapeutic agent including the telomerase-derived peptide results in decreased factors causing one of the disease and disorder symptoms requiring the target-specific treatment, such as cancer, in a tumor disease treatment.Type: ApplicationFiled: November 9, 2016Publication date: May 11, 2017Applicant: GemVax & KAEL Co., Ltd.Inventors: Sang Jae KIM, Hiroyuki Abe, Hwa In Jang, Jung Soon Ha
-
Patent number: 9631184Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: GrantFiled: September 17, 2013Date of Patent: April 25, 2017Assignee: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae Kim
-
Publication number: 20170058001Abstract: Disclosed are: a composition for organ, tissue or cell transplantation, containing, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1, a peptide having at least 80% sequence homology with the amino acid sequence, or a peptide which is a fragment thereof; a kit comprising the composition; or a method using the composition. By using the composition, the kit, or the method, the viability and/or function of an organ, tissue, or cell after transplantation are strengthened and an organ, tissue or cell isolated from a living body is preserved temporarily without damage.Type: ApplicationFiled: May 28, 2014Publication date: March 2, 2017Applicant: GemVax & KAEL Co., Ltd.Inventor: Sang Jae KIM
-
Patent number: 9572858Abstract: The present invention relates to a composition for treating and preventing benign prostatic hyperplasia, and a method for treating benign prostatic hyperplasia using same. More specifically, the present invention relates to a composition comprising telomerase-derived peptides for effectively treating and preventing benign prostatic hyperplasia and a method for treating benign prostatic hyperplasia using same. The composition comprising the peptide according to the present invention exhibits excellent effectiveness in treating and preventing benign prostatic hyperplasia.Type: GrantFiled: April 22, 2016Date of Patent: February 21, 2017Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Patent number: 9572900Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 178, a fragment of any one sequence of SEQ ID NO: 2 to SEQ ID NO: 178, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: GrantFiled: September 17, 2013Date of Patent: February 21, 2017Assignee: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Publication number: 20170028035Abstract: The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-? signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis.Type: ApplicationFiled: April 10, 2015Publication date: February 2, 2017Applicant: GemVax & KAEL Co., Ltd.Inventor: Sang Jae KIM
-
Patent number: 9540419Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating a variety of different types of inflammatory diseases.Type: GrantFiled: May 7, 2013Date of Patent: January 10, 2017Assignee: GemVax & Kael Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Publication number: 20160375091Abstract: The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance.Type: ApplicationFiled: December 17, 2014Publication date: December 29, 2016Applicant: GemVax & KAEL CO., lTD.Inventor: Sang Jae KIM
-
Patent number: 9527888Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: GrantFiled: March 15, 2013Date of Patent: December 27, 2016Assignee: GemVax & KAEL Co., Ltd.Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
-
Publication number: 20160296604Abstract: The present invention relates to a peptide having angiogenesis inhibition activity and pharmaceutical composition comprising thereof. More specifically, the present invention relates to the pharmaceutical composition for inhibiting angiogenesis comprising the peptide as a peptide derived from telomerase.Type: ApplicationFiled: November 21, 2014Publication date: October 13, 2016Applicant: GemVax & KAEL Co., Ltd.Inventor: Sang Jae KIM
-
Publication number: 20160250279Abstract: The present invention relates to a composition for treating and preventing benign prostatic hyperplasia, and a method for treating benign prostatic hyperplasia using same. More specifically, the present invention relates to a composition comprising telomerase-derived peptides for effectively treating and preventing benign prostatic hyperplasia and a method for treating benign prostatic hyperplasia using same. The composition comprising the peptide according to the present invention exhibits excellent effectiveness in treating and preventing benign prostatic hyperplasia.Type: ApplicationFiled: April 22, 2016Publication date: September 1, 2016Applicant: GemVax & KAEL Co., Ltd.Inventor: Sang Jae KIM
-
Publication number: 20160158374Abstract: The present invention relates to a cell-penetrating peptide derived from telomerase, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide according to the present invention. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained.Type: ApplicationFiled: July 11, 2014Publication date: June 9, 2016Applicant: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20160151512Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: ApplicationFiled: July 11, 2013Publication date: June 2, 2016Applicants: GemVax & KAEL Co., Ltd.Inventor: Sang Jae Kim
-
Publication number: 20160137695Abstract: Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.Type: ApplicationFiled: June 23, 2014Publication date: May 19, 2016Applicant: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20160120966Abstract: Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1?, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.Type: ApplicationFiled: June 5, 2014Publication date: May 5, 2016Applicant: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20160082089Abstract: The present disclosure relates to a composition for treating and preventing an ischemic injury. More particularly, it relates to a composition containing a peptide derived from a telomerase, which is effective in treating and preventing an ischemic injury. The peptide according to the present disclosure, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof, has a superior effect of treating and preventing an ischemic injury. Accordingly, a composition containing the peptide may be effectively used for an ischemic injury, particularly for an ischemic-reperfusion injury.Type: ApplicationFiled: April 18, 2014Publication date: March 24, 2016Applicant: GEMVAX & KAEL CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20160008438Abstract: Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis.Type: ApplicationFiled: May 10, 2013Publication date: January 14, 2016Applicants: KAEL-GEMVAX CO., LTD.Inventor: Sang Jae KIM
-
Publication number: 20160002613Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.Type: ApplicationFiled: September 17, 2013Publication date: January 7, 2016Applicant: GemVax & KAEL Co., Ltd.Inventor: Sang Jae KIM
-
Publication number: 20150353903Abstract: The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects.Type: ApplicationFiled: May 10, 2013Publication date: December 10, 2015Applicants: KAEL-GEMVAX CO., LTD.Inventor: Sang Jae KIM